Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Moderna stock extends decline after leaked data on melanoma vaccine trial
23.10.2026 13:49
Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
23.10.2026 13:17
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.
Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%
23.10.2026 10:30
Key Stats for Merck StockPrice change for Merck stock in last 6 months: 28%$MRK Stock Price as of Oct. 21: $14752-Week High: $157$MRK Stock Price Target: $159__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Moderna and Merck (MRK:NYSE) shared results from a large melanoma trial on Thursday.
Moderna Stock Slides Again Friday: What's Going On?
23.10.2026 08:35
Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.
U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI
23.10.2026 08:09
The prohibitions could cut off Big Pharma from Chinese biotechs—the source of many promising cancer treatments
How Unusual Is Zoetis's Latest Sales Growth?
22.10.2026 03:34
For questions about this article or underlying research, email help@trefis.com.
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
21.10.2026 13:00
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
21.10.2026 10:45
RAHWAY, N.J., October 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC). This approval, which also covers KEYTRUDA SC® [known as KEYTRUDA QLEXTM
Global Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use Solutions
21.10.2026 08:15
Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Bioprocessing Support Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bioprocessing support services market is experiencing rapid expansion, driven by increasing biopharmaceutical production, greater outsourcing of development and manufacturing
Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and Lonza
21.10.2026 08:14
Boost ROI with integrated single-use bioreactors that reduce contamination, setup time, cleaning, footprint and operating costs while improving scalability.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Cell Culture Media and Single-Use Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering. Cell Culture Media and Single-Use Reagents Market Poised to Reach $8.34 Billion by 2030 The global cell culture media and single-use reagents market is experiencing rapid expansion, sup
Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGR
21.10.2026 08:13
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global upstream bioprocessing equipment market is projected to grow rapidly as biopharmaceutical manufacturers expand production capacity and adopt more flexible, efficient manufacturing technologies. The market is expected to increase from $11.13 billion in 2025 to $12.32 billion in 2026, representing a compound annual growth rate (CAGR) of 10.
Cell-Based Biological Reagents Global Market Report 2026-2030 | Capitalize on 8.6% CAGR | Thermo Fisher, Merck, Danaher and Lonza Lead the Industry
21.10.2026 08:10
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Cell-based Biological Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell-based biological reagents market is projected to grow from $13.78 billion in 2025 to $14.93 billion in 2026, representing a compound annual growth rate (CAGR) of 8.3%. By 2030, the market is expected to reach $20.74 billion, expanding at a CAGR of 8.6% during the forecast period. Historical market growth has been supported by the expan
Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With Resectable Muscle-Invasive Bladder Cancer
21.10.2026 06:47
European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
20.10.2026 11:28
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
How Earnings Beat At Amgen Stock Has Changed Its Investment Story
20.10.2026 03:23
Amgen recently reported a 10% rise in second quarter revenue, continued to beat earnings and sales estimates, and maintained a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025. The combination of consistent estimate beats, modest upward earnings revisions and faster dividend growth than Merck signals a business leaning on disciplined capital returns as well as expanding newer therapies. We will look at how Amgen's investment narrative is influenced by sustained dividend...
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
19.10.2026 03:15
Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.
Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock
17.10.2026 04:21
Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine
15.10.2026 15:27
Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “International Concentrated Growth Strategy”. A copy of the letter can be downloaded here. The strategy outperformed its benchmark in the third quarter of 2026, as strong company-specific developments in biotechnology and digital platforms helped offset weakness in parts of […]
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
15.10.2026 12:20
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
15.10.2026 12:00
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.